Kornimate/medical-research-clean huggingface dataset:
earlier diagnosis and better treatment mission related to the cohort programme

Conditions: Parkinson Disease

Summary: the luxembourg parkinson's study is an ongoing longitudinal nationwide monocentric observational study. it collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (hipp et al., 2018). the cohort consists of more than 1,600 participants from luxembourg and the greater region, comprising patients with typical pd or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. to provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on pd, the investigators have implemented an open-source digital platform that has been partly harmonized with other international pd cohort studies. this effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). all data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.


Eligibility criteria:
inclusion criteria: * subjects with neurodegenerative disease or having parkinson's disease (typical pd or atypical parkinsonism) * subjects of all genders with a full capacity of consent * subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement * subjects of at least 18 years of age at the time of inclusion exclusion criteria: * refusal to sign the informed consent * limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion * active cancer * pregnant women * underage subjects of less than 18 years of age * refusal to comply with mandatory sample collection * for invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Keywords: parkinson's disease longitudinal cohort stratification risk factors
overcoming stigma and improving outcomes for suds through education, engagement, and empowerment

Conditions: Opioid Use Disorder

Summary: c4 innovations (c4) and partners at yale university (yale) and the west haven va medical center (whva) proposed to develop and test oasis (overcoming and addressing stigma in substance use disorders), a web-based educational platform for primary care clinicians and individuals with opioid use disorder. the major aims of the study were to: 1. develop a prototype of oasis for patients with opioid use disorder (oud) and primary care clinicians; conduct usability testing. 2. pilot oasis with a small sample of individuals with untreated oud and their clinicians to determine feasibility, acceptability, and preliminary product effectiveness for a phase ii effectiveness trial. after development of the prototype, the c4-yale-whva team planned to test oasis with patients (n = 30) and clinicians (n = 5) using validated measures and qualitative interviews to assess usability, satisfaction, knowledge, empowerment, and stigma.


Eligibility criteria:
inclusion criteria: for providers: * clinically active and seeing patients; * having a device with internet access to use the oasis prototype * english speaking * willing and able to complete data collection activities. for patients: * diagnosed oud * unmet substance use treatment need * has an upcoming primary care visit scheduled for the intervention period (1-2 months) * english speaking * has access to a device with internet access to use the oasis prototype * willing and able to complete data collection activities exclusion criteria: patient participants will be excluded from this study if they: 1) currently receiving or have received medication for opioid dependence.
the effect of per oral immunotherapy in severe milk, peanut and egg allergy in adults

Conditions: Food Allergy

Summary: the aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. this is the second part of the oral immunotherapy study in adults at skin and allergy hospital. the diagnosis of food allergy is verified with positive history, skin prick tests, egg and milk allergen specific ige (immunoglobulin e) antibodies. in addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. oit (oral immunotherapy) is performed according to a detailed plan. lung function parameters are followed before oit and and a year after oit.

30 patients with milk allergy (at least 18 year olds), 30 patients with peanut allergy and 30 patients with egg allergy are treated with oit. the diagnosis of food allergy is verified with positive history, skin prick test, egg and milk allergen specific ige antibodies. in addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. quality of life, anxiety and patient history data is collected by questionnaires. all the patients undergo a spirometry with a bronchodilatator test, exhaled nitric oxide test and a methacholine challenge before and a year after oral immunotherapy. all the patients undergoing oral immunotherapy are prescribed with emergency medication such as antihistamine tablets, prednisolon tablets (40mg for three days in adults), epinephrine autoinjector (300 µg per dose) and salbutamol or terbutaline inhalator.

Eligibility criteria:
inclusion criteria: * severe milk, peanut or egg allergy verified with positive symptom history, skin prick tests and serum ige tests and a challenge test exclusion criteria: * instable cerebrovascular or heart disease, active autoimmune disease or cancer, or current use of betablockers. * poorly controlled asthma or fev1 \< 70% (fev1\< -2sd)

Keywords: oral immunotherapy milk peanut egg adult
temporomandibular joint dysfunction prevalence and oral habits, food consumption frequency and eating behaviour

Conditions: Temporomandibular Joint Disorders; Oral Habits; University Students

Summary: this study was planned to investigate the prevalence of tmd in university students and to determine possible predisposition factors by evaluating oral habits, food consumption frequency and eating behaviors thought to be related to tmd.

no study has been found examining the relationship between temporomandibular joint dysfunction (tmd) and oral habits, food consumption frequency and eating behavior. in this context, it is thought that understanding the relationships mentioned may provide different perspectives and help develop an effective treatment program.

Eligibility criteria:
inclusion criteria: 1. continuing undergraduate education at faculties/colleges affiliated with karadeniz technical university 2. being able to read and write in turkish 3. agreeing to participate in the study exclusion criteria: 1. having a local or systemic disease that may affect oral and jaw health 2. having had an operation / trauma to the cervical region or tmj

Keywords: temporomandibular joint dysfunction oral habits food consumption eating behaviour
pinpoint feasibility study

Conditions: Prostate Cancer; Image Guided Radiotherapy

Summary: this feasibility study is investigating the application of magnetic resonance imaging (mri) and transperineal ultrasound (tpus) to visualise potential sites of relapse and surrounding normal tissue in patient having post-operative prostate cancer radiotherapy. structure visualisation on mri and tpus will be compared to current standard computer tomography (ct) and cone-beam computer tomography (cbct) imaging.

approximately 47,000 men are diagnosed with prostate cancer yearly in the uk, 15% of which receive surgery (radical prostatectomy) as primary treatment. of these men one third develop recurrence after prostatectomy and are offered post-operative radiotherapy. radiotherapy is targeted at the area where the prostate used to be, this includes potential relapse sites (prs); vesicourethral anastomosis, bladder neck and retrovesicle space. when planning post-operative radiotherapy, the lack of a visible target means surrounding normal tissue is used to guide clinical target volume (ctv) delineation. the ctv is the area of tissue to be treated to the full radiotherapy prescription and includes prs. typically, the ctv is defined on a radiotherapy planning computer tomography (ct) scan. the ctv lies adjacent to the bladder and rectum and is highly susceptible to positional changes influenced by organ filling. to identify and correct for ctv displacement during daily radiotherapy a cone-beam ct (cbct) is acquired, this is an image similar to a ct scan but taken immediately prior to treatment delivery. ct visualisation of prs has been reported as inadequate, increasing the risk of missing or miss-identifying ctv structures during radiotherapy planning and delivery. to compensate for restricted visualisation on ct and cbct an additional 1cm circumference around the ctv is treated to the prescription dose, this volume is referred to as the planning target volume (ptv). this margin reduces the risk of missing the target however its inclusion of normal tissue increases the risk of patient toxicity. we propose that visualisation of prs and surrounding normal tissue structures is enhanced on magnetic resonance imaging (mri) compared to ct and on transperineal ultrasound (tpus) compared to cbct. this project investigates the reality of this statement by quantifying the confidence and reliability with which anatomical structures can be identified and delineated on all four image types.

Eligibility criteria:
inclusion criteria: * patient has undergone radical prostatectomy * histologically confirmed prostate cancer * patient due to receive post-operative prostate bed +/- pelvic lymph node radiotherapy * who performance status 0-1 * age ≥ 18 years * written informed consent exclusion criteria: * recruitment into pops trial * contraindications to mri such as having a pacemaker or non-mri compatible implanted device
a study to evaluate the efficacy and safety of herceptin® (trastuzumab) in combination with arimidex® (anastrozole) an aromatase inhibitor compared to arimidex® alone in patients with metastatic breast cancer

Conditions: Breast Cancer

Summary: this 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (herceptin®) to daily oral anastrozole (arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (her2) overexpressing metastatic breast cancer (er+ve and/or pr+ve). patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of herceptin® 2 mg/kg iv. the anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.


Eligibility criteria:
inclusion criteria: * postmenopausal women; * metastatic breast cancer suitable for endocrine therapy; * positive hormone receptor status; * human epidermal growth factor receptor 2 (her2) overexpression. exclusion criteria: * patients on hormone replacement therapy; * previous chemotherapy for metastatic disease; * uncontrolled cardiac disease and history of cardiac failure.
prospective multicenter cohort study evaluating the incidence and risk factors for problem gambling among young adults with first-episode psychosis

Conditions: Gambling Disorder; Psychotic Disorders

Summary: the aims of this propsective cohort study are to get a better understanding of the association between problem gambling and psychotic disorders among young adults with first-episode psychosis. the main questions to be answered are: 1. what is the incidence of problem gambling in this population? 2. what are the predictors of problem gambling in this population? to do so, putative predictors of problem gambling will be analyzed using cox regression models: * sociodemographics (e.g., age, gender identity, ethnicity, level of education, employment); * psychiatric comorbidities (e.g., substance use disorders, cluster b personality disorders); * antipsychotic use (first/second-generation, third-generation \[aripiprazole, brexpiprazole, cariprazine\]); * prior gambling history.

all cox regression models will be adjusted for site-effect. further multivariable models will be constructed to examine the association between antipsychotic use (as continuous exposure) and incident pbg using the directed acyclic graphs approach to adjust for confounders.

Eligibility criteria:
inclusion criteria: * 18 to 35 years old; * diagnosis of first-episode psychosis (i.e., dsm-5 diagnosis of schizophrenia spectrum and other psychotic disorders, as well as dsm-5 bipolar disorder with psychotic features). exclusion criteria: * active/prior pbg at te time of admission; * loss to follow-up within first three months; * dsm-5 diagnosis of psychotic disorder due to a medical condition; * severe intellectual disability.

Keywords: gambling psychotic disorder schizophrenia cohort multicenter prospective observational incidence risk factors
taiwan diabesity study:comparison with mild obese t2dm patients who under metabolic surgery

Conditions: Diabetes

Summary: t2dm has become a major health burden for our society. more and more data support the relative effectiveness of gastrointestinal metabolic surgery, known as bariatric surgery, in the remission of t2dm of bmi less35. the metabolic surgery guidelines of idf recommend bmi over 27.5 in asia. the evidence reviewed above strongly points to the need for a large randomized, controlled trial to evaluate the risks and benefits of obesity surgery in the treatment of type 2 diabetes mellitus. this study is expected to provide very significant findings about the natural course of diabetes in obese diabetic patients.

this study will recruit 200 obese t2dm patients at msgh, for a total of 1000 in taiwan. the inclusion criteria are those with t2dm more than 6 months, under medical management in diabetes center, bmi over 25, age between 20 and 67 years. the goals of this study are to evaluate the nature course of the diabetes for 10 years. the primary outcomes for the treatment will be assessed every year after intervention and will be composite of cvd risk factor; specifically, the proportion of patients with hba1c \< 7%, ldl cholesterol \< 100 mg/dl and systolic blood pressure \< 140 mmhg.

Eligibility criteria:
inclusion criteria: * diabetic mellitus type 2 medically controlled at diabetes center for at least six months * bmi over 25 * age between 20 and 67 exclusion criteria: * diagnosed with cancer within past five years * hiv positive * active tb patients * cv events in past six months * serum cretinine over 2.0 mg/dl * c-peptide bellow 1.0 ng/ml in past three months * diabetic retinopathy; vision bellow 0.1 * cushing's syndrome * history of organ transplant * history of bariatric surgery * history of alcohol or drug dependency in past five years * psychological problems likely to interfere with adherence to protocol
efficacy study of iguratimod combined with tofacitab in patients with rf positive/negative rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Therapy

Summary: rheumatoid arthritis (ra) is a chronic progressive autoimmune disease with predominantly joint involvement. to compare the efficacy and difference between elamod and tofacitib in the treatment of rheumatoid factor-positive and negative rheumatoid arthritis in ra patients with poor outcome after csdmards dosing, in order to better inform the clinical management.

this is an open, controlled, interventional clinical study enrolling patients with active ra who meet the following entry row criteria, and treating patients with igu 25 mg bid + tofacitinib 5 mg bid for the intervention. the screening period was defined as the screening visit was conducted within 1 month prior to the baseline visit, and efficacy and safety assessments were performed at time points 0, 4, 12, 18, and 24 weeks from the time the subject was treated with the study protocol (see efficacy and safety endpoints for details), and study subjects were asked to come to the hospital for follow-up within ±3 days of the corresponding follow-up point.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-65 years old 2. body weight not less than 40kg 3. patients with a clear diagnosis of rheumatoid arthritis (ra) who meet the diagnostic criteria for ra introduced by the acr in 1987 or acr\\eular in 2010 4. joint function grade ii-iii 5. active rheumatoid arthritis (defined as active rheumatoid arthritis if the following three conditions are met: ① ≥ 6 joints swollen \[66 joints count\] ② ≥ 6 joints tenderness \[68 joints count\] ③erythrocyte sedimentation rate (esr) \> 28 mm/h or c-reactive protein (crp) \> 1.0 mg/dl) 6. the patients have been treated with csdmards for ≥ 3 months and have been treated with stable doses of csdmards for 4 consecutive weeks prior to study entry, with poor therapeutic outcomes and are being considered for treatment with a combination of biologics (bdmards) (according to the 2018 china rheumatoid arthritis treatment guidelines, poor outcomes, i.e., no significant improvement in ra disease activity within 3 months or failure to achieve treatment goals within 6 months) 7. subjects must be able and willing to perform subcutaneous (sc) injections on their own, or a qualified person must be available to perform sc injections 8. if taking glucocorticosteroids, prednisone should be ≤10mg or other hormone at a dose equivalent to prednisone and the dose should be kept constant for at least 28d 9. understand the purpose of the trial and the test procedures and sign a written informed consent form voluntarily exclusion criteria: 1. patients who have used potent immunosuppressants (such as cyclophosphamide, cyclosporine, azathioprine, etc.), tripterygiam glycosides and so on that affect the evaluation of efficacy in previous rheumatoid arthritis treatment , and who have stopped taking them for less than 4 weeks 2. history of allergy to relevant test drugs 3. previously treated with bdmards 4. subject has recently received a live vaccine, or plans to use any live vaccine during the study
retrospective database review at ltc and snfs

Conditions: Non-Healing Ulcer of Skin; Autofluorescence Imaging

Summary: the goal of this observational study is to compare the differences in wound outcomes when the moleculight imaging procedure is used in combination with standard of care wound assessment in long term care and skilled nursing facilities. the main outcome studied is healing of ulcers after 12-weeks, along with other outcomes such as occurrence of infection, complications, and antimicrobial use. medical records from the past were reviewed, where patients receiving the moleculight procedure were compared to those who did not.


Eligibility criteria:
inclusion criteria: * were first treated by wound care plus llc during time periods from jan 2019-feb 2020 (standard of care cohort) and may 2021-mar 2022 (moleculight cohort) * received at least one debridement, as indicated by cpt codes 11042, 11045, 97597, and/or 97598, during the study admission period * were treated by a wound care plus llc provider for at least 4 calendar weeks during the study period * were treated in a snf or ltc setting during the study admission period * were covered by medicare of missouri during the study admission period * had at least one chronic ulcer with icd-10 diagnosis codes l89, l97, l98, or l97/l98 in combination with e11 during the study admission period * moleculight cohort only: at least one moleculight imaging procedure during the study admission period, indicated by cpt code 0598t exclusion criteria: * did not receive at least one debridement, as indicated by cpt codes 11042, 11045, 97597, and/or 97598, during the study admission period * received care from wound care plus llc for less than 4 calendar weeks during the study admission period * were not treated in a snf or ltc setting during the study admission period * were not covered by medicare of missouri during the study admission period * did not have a chronic ulcer with icd-10 diagnosis codes l89, l97, l98, or l97/l98 in combination with e11 during the study admission period * moleculight cohort only: did not receive a moleculight imaging procedure during the study admission period, indicated by cpt code 0598t

Keywords: chronic wounds bacterial loads fluorescence imaging moleculight long-term care skilled nursing facility
protocol for gfr measurement using iohexol (scope-plus) - a substudy of the scope study

Conditions: Chronic Kidney Diseases

Summary: scope-plus is an optional substudy of the observational scope study (screening for chronic kidney disease among older people across europe, nct02691546). the objective of the scope-plus study is to derive new equations based on innovative and novel biomarkers of ckd function and compare its accuracy to measure gfr in the population older than 75 years.

scope-plus is an optional substudy of the scope cohort study (screening for chronic kidney disease among older people across europe, nct02691546). scope has retrieved data on a wide panel of biomarkers of ckd in a large study cohort enrolling about 2,450 older people in italy, spain, germany, austria, netherlands, poland and israel. the innovative biomarkers have been already validated by the literature, and include e.g. cystatin c (cysc), β-trace protein (btp), and beta2-microglobulin. others promising novel biomarkers of ckd, based on metabolomic and proteomic determinations or other techniques have been evaluated. the objective of the scope-plus study is to to verify the accuracy of newly developed equations based on innovative and novel biomarkers of ckd function by calculating the percentage of estimates within 30% (p30) of the measured gfr (mgfr). the mgfr will be obtained by the assessment of nonradioactive iohexol clearance. patients previously enrolled in the scope study, are invited to participate in this additional protocol. iohexol is an iodinated contrast medium with characteristics similar to those of inulin, being freely filtered by the glomerulus, neither secreted nor reabsorbed by the renal tubules and recovered almost 100% in the urine. these characteristics made it an ideal agent for the determination of the renal function.

Eligibility criteria:
inclusion criteria: * to be eligible for this study, subjects must have been enrolled in the scope study exclusion criteria for substudy: * a thyroid-stimulating hormone level less than 0.3 mlu/l * a known iodine allergy * oedema * ascites * clinically symptomatic heart failure

Keywords: glomerular filtration rate older people ioexol